Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

1701335

	registered interest
	date	16/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Blood Cancer: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 7 March 2024 to Question 15636 on Blood Cancer: Drugs, on what date her Department first became aware of challenges presented by the appraisal of combination therapies; and what solutions her Department is considering with NHS England to ensure continued equal access to combination medicines for multiple myeloma across the UK.
	tabling member constituency	Strangford
	tabling member printed	Jim Shannon
	uin	21993
	answer	answer is ministerial correction date of answer 24/04/2024 answer text <p>NHS England, the National Institute for Health and Care Excellence (NICE), and the Association of the British Pharmaceutical Industry (ABPI) worked closely with the Competition and Markets Authority (CMA) over a number of years on the CMA’s statement on combination therapies, published in November 2023.</p><p>The steps taken by the CMA provide a clear commercial position that means that deals involving multiple drugs licensed by different companies can now be agreed under specific circumstances. This has been welcomed by the ABPI as an opportunity to unlock the door to more transformative combination therapies on the National Health Service.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 24/04/2024 15:37:14 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4131 label Biography information for Jim Shannon

1701336

	registered interest
	date	16/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Drugs: Procurement
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if she will have discussions with NHS England on the effectiveness of its Commercial Framework in tackling challenges presented by the appraisal and reimbursement system when applied to combination medicines and medicines with multiple indications.
	tabling member constituency	Strangford
	tabling member printed	Jim Shannon
	uin	21994
	answer	answer is ministerial correction date of answer 24/04/2024 answer text <p>As part of the 2024 voluntary scheme for branded medicines pricing, access, and growth, NHS England has committed to undertake two consultations on its Commercial Framework for New Medicines. The first of these will be launched in summer 2024 and will align with the Competition and Markets Authority’s (CMA) statement on combination medicines. In addition, it will be more explicit about the approach taken for assessing the eligibility of medicines treating multiple indications to qualify for indication specific pricing mechanisms.</p><p>Following the first consultation, a revised framework will be published by the end of 2024, and engagement with pharmaceutical companies and patient groups on these issues is already taking place.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 24/04/2024 15:42:59 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4131 label Biography information for Jim Shannon

1701764

	registered interest
	date	17/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Community Health Services: Nurses
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how many nurses have worked in NHS community health services on average in each of the last 10 years.
	tabling member constituency	Bristol South
	tabling member printed	Karin Smyth
	uin	22321
	answer	answer is ministerial correction date of answer 24/04/2024 answer text <p>NHS England publishes Hospital and Community Health Services workforce statistics for England. These include staff working for hospital trusts and integrated care boards, but excludes staff working for other providers such as in primary care, general practice or social care. This data is drawn from the Electronic Staff Record, the human resources system for the National Health Service.</p><p>The latest statistics on NHS nursing workforce by area of nursing and care setting can be found in the link below within the ‘Nurses by Setting’ worksheet:</p><p><a href="https://files.digital.nhs.uk/9A/948DEC/NHS%20Workforce%20Statistics%2C%20January%202024%20England%20Provisional%20statistics.xlsx" target="_blank">https://files.digital.nhs.uk/9A/948DEC/NHS%20Workforce%20Statistics%2C%20January%202024%20England%20Provisional%20statistics.xlsx</a></p><p>Within this data there are nurses working in community settings within several staff groups including community health nurses, community learning disability nurses, community mental health nurses, and as health visitors.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 24/04/2024 15:50:28 answering member 4044 label Biography information for Andrew Stephenson previous answer version 29527 answering member constituency Pendle answering member printed Andrew Stephenson answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4444 label Biography information for Karin Smyth

1701855

	registered interest
	date	17/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Pregnancy: Screening
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what information her Department holds on the number of non-invasive pre-natal tests branded as NIFTY and manufactured by BGI Group have been sold in the UK.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	22292
	answer	answer is ministerial correction date of answer 24/04/2024 answer text <p>The Department and NHS England do not hold information on the sales within the United Kingdom of the non-invasive pre-natal tests branded as NIFTY, manufactured by BGI Group. The NHS Supply Chain, who manage the sourcing, delivery, and supply of healthcare products, services, and food for National Health Service trusts and healthcare organisations across England, develop procurement frameworks which enable NHS organisations to buy goods and services from suppliers. NHS Supply Chain has confirmed that non-invasive pre-natal tests branded as NIFTY and manufactured by BGI Group, are not on their procurement framework.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 24/04/2024 15:30:31 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	3960 label Biography information for Henry Smith

1701944

	registered interest
	date	17/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Neuromuscular Disorders: Health Services
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what support exists for those with (a) Huntington’s disease and (b) other complex neurological conditions.
	tabling member constituency	Watford
	tabling member printed	Dean Russell
	uin	22414
	answer	answer is ministerial correction date of answer 24/04/2024 answer text <p>Integrated care boards (ICBs) are responsible for commissioning most services for people with neurological conditions, including those with Huntington’s disease. At a national level, NHS England commissions the specialised elements of neurological care that patients may receive from 27 specialised neurological treatment centres across England. NHS England’s RightCare toolkit and Getting It Right First Time programme aim to improve care for people with neurological conditions, by reducing variation and delivering care more equitably across England.</p><p>New optimal clinical pathways for a range of neurological conditions were developed by the National Neurosciences Advisory Group, which ceased operation in 2022. These pathways set out what good treatment, care, and support should look like across a range of neurological conditions. They also help to guide and facilitate the commissioning of high-quality, effective neurology services by ICBs. The optimal clinical pathway for movement disorders outlines the care pathway that patients with Huntington’s disease should receive. Further information on the optimal clinical pathways are available at the following link:</p><p><a href="https://www.nnag.org.uk/optimum-clinical-pathways" target="_blank">https://www.nnag.org.uk/optimum-clinical-pathways</a></p><p>The Department funds research on neurological conditions through the National Institute for Health and Care Research (NIHR), and between 2018/19 and 2022/23, the Department spent £272.1 million on research into neurological conditions. This covers research into conditions such as Huntington’s disease, Parkinson’s disease, epilepsy, and multiple sclerosis. In 2022/23, the most recent year for which we have data, the Department, via the NIHR, spent £65.3 million on research into neurological conditions.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 24/04/2024 15:24:11 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4812 label Biography information for Dean Russell

1702143

	registered interest
	date	18/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Stonewall: Finance
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how much funding her Department has given to Stonewall since 2019.
	tabling member constituency	South Holland and The Deepings
	tabling member printed	Sir John Hayes
	uin	22452
	answer	answer is ministerial correction date of answer 24/04/2024 answer text <p>Our financial records show a total sum of £6,000 paid to Stonewall between the years 2019 to 2020, as part of the Diversity Champions annual membership. This is broken down into £3,000 between 1 January 2019 and 31 December 2019, and £3,000 between 1 January 2020 and 31 December 2020. As of February 2021, the Department’s membership with Stonewall lapsed, with no further payments made from 2021 to date.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 24/04/2024 14:52:48 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	350 label Biography information for Sir John Hayes

1702222

	registered interest
	date	18/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Mental Health
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what recent assessment she has made of the effectiveness of the BALM programme.
	tabling member constituency	York Central
	tabling member printed	Rachael Maskell
	uin	22587
	answer	answer is ministerial correction date of answer 24/04/2024 answer text <p>NHS England is currently undertaking a review of how health and wellbeing support could be delivered more effectively. As part of this review, the team will: assess NHS England’s current contracts; work with integrated care boards, National Health Service trusts, and primary care organisations to understand the scale and impact of locally provided provision; and work with system partners and stakeholders including royal colleges, the voluntary sector, and the independent sector to understand how demand for these services has changed over recent years.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 24/04/2024 15:00:47 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4471 label Biography information for Rachael Maskell

1702405

	registered interest
	date	19/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Clinical Trials: Children
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps she is taking to ensure (a) transparency and (b) parental consent in clinical trials involving children.
	tabling member constituency	Slough
	tabling member printed	Mr Tanmanjeet Singh Dhesi
	uin	22789
	answer	answer is ministerial correction date of answer 24/04/2024 answer text <p>There are legal measures in place to ensure informed consent in clinical trials, through the Medicines for Human Use (Clinical Trials) Regulations 2004. Parental consent for clinical trials investigating medicines which involve children is also legislated for via the same Regulations.</p><p>Promoting and ensuring transparency is central to the role of the Health Research Authority to facilitate safe and ethical research as defined in the Care Act 2014. This includes clinical trials involving children.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 22790 question first answered 24/04/2024 16:22:38 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4638 label Biography information for Mr Tanmanjeet Singh Dhesi

1702406

	registered interest
	date	19/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Clinical Trials
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what measures are in place to ensure informed consent in clinical trials.
	tabling member constituency	Slough
	tabling member printed	Mr Tanmanjeet Singh Dhesi
	uin	22790
	answer	answer is ministerial correction date of answer 24/04/2024 answer text <p>There are legal measures in place to ensure informed consent in clinical trials, through the Medicines for Human Use (Clinical Trials) Regulations 2004. Parental consent for clinical trials investigating medicines which involve children is also legislated for via the same Regulations.</p><p>Promoting and ensuring transparency is central to the role of the Health Research Authority to facilitate safe and ethical research as defined in the Care Act 2014. This includes clinical trials involving children.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 22789 question first answered 24/04/2024 16:22:38 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4638 label Biography information for Mr Tanmanjeet Singh Dhesi

1712667

	registered interest
	date	22/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cancer: Screening
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps her Department is taking to (a) trial and (b) roll-out early cancer screening.
	tabling member constituency	Strangford
	tabling member printed	Jim Shannon
	uin	22951
	answer	answer is ministerial correction date of answer 24/04/2024 answer text <p>In England, early cancer screening is already in place for cervical, breast, and bowel cancer. The UK National Screening Committee (UK NSC) does not currently recommend screening for prostate cancer due to the inaccuracy of the current best test, called Prostate Specific Antigen. We are providing £16 million of funding to Prostate Cancer UK's £42 million trial, which is aimed at helping us find a way of catching prostate cancer in men as early as possible. The UK NSC is also commissioning evidence for six possible approaches to targeted prostate screening for those at higher risk. The UK NSC will publish its recommendations when complete.</p><p>NHS England is responsible for the running of the Targeted Lung Health Check Programme, and its conversion to a nationally rolled out NHS Targeted Lung Cancer Screening Programme by 2030.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 24/04/2024 14:48:02 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4131 label Biography information for Jim Shannon